{"id":2058,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2008-06-20","marketCap":1973.13134765625,"name":"Iovance Biotherapeutics Inc","phone":"16502607120","outstanding":255.9199981689453,"symbol":"IOVA","website":"https://www.iovance.com/","industry":"Biotechnology"},"price":7.5575,"year":2023,"month":12,"day":15,"weekday":"Friday","title":"The Impact of Currency Fluctuations on Iovance Biotherapeutics Inc Multinational Stock","date":"2023-12-15","url":"/posts/2023/12/15/IOVA","content":[{"section":"Introduction","text":"Iovance Biotherapeutics Inc is a multinational company engaged in the development and commercialization of novel cancer immunotherapies. As a result of its international operations, the company is exposed to currency risk, which refers to the potential for financial losses or gains due to fluctuations in exchange rates. Currency risk can have significant implications for Iovance Biotherapeutics Inc's stock performance and financial stability."},{"section":"Case Study 1: Brexit and GBP Fluctuations","text":"One notable case study is the impact of Brexit on Iovance Biotherapeutics Inc's stock. Following the Brexit referendum in 2016, the British pound (GBP) experienced significant volatility. As Iovance Biotherapeutics Inc has operations in the United Kingdom, fluctuations in the GBP-to-USD exchange rate directly affected its financial results. A decline in the GBP would result in lower revenue when converted back to USD, potentially leading to a decrease in stock value. Conversely, a strengthening GBP would have the opposite effect. This illustrates the vulnerability of Iovance Biotherapeutics Inc's stock to currency fluctuations."},{"section":"Case Study 2: Emerging Market Currency Instability","text":"Another case study involves the impact of currency instability in emerging markets on Iovance Biotherapeutics Inc's stock. Many multinational companies, including Iovance Biotherapeutics Inc, have operations in countries with less stable economies and currencies. When the currencies of these markets experience significant depreciation or volatility, the financial performance of the company can be adversely affected. Repatriated earnings from these markets would be reduced when converted back to the reporting currency (e.g., USD), potentially leading to a decrease in stock value. This highlights the exposure of Iovance Biotherapeutics Inc's stock to emerging market currency risk."},{"section":"Balanced Assessment of Currency Risk","text":"Currency risk is a double-edged sword that can present both opportunities and challenges for Iovance Biotherapeutics Inc's multinational stock. On the positive side, favorable currency movements can enhance the company's financial performance and increase its stock value. For example, if the USD strengthens against other currencies, the conversion of foreign revenue into USD would lead to higher reported earnings. On the other hand, adverse currency fluctuations can pose significant risks. Instability in key markets or unexpected depreciations can result in diminished earnings and a decline in stock value. It is essential for investors to carefully assess the potential impact of currency risk on Iovance Biotherapeutics Inc's stock while considering the company's international exposure and currency hedging strategies."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1702388700,"headline":"Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?","id":124476717,"image":"https://g.foolcdn.com/editorial/images/757942/growth-stock.jpg","symbol":"IOVA","publisher":"Yahoo","summary":"Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint.","url":"https://www.fool.com/investing/2023/12/12/better-growth-stock-viking-therapeutics-or-iovance/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;.tsrc=rss"},{"category":"company","date":1702387535,"headline":"Iovance Biotherapeutics: The Easiest Money May Have Been Made, But Approval Does Seem Likely","id":124462220,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1504545560/image_1504545560.jpg?io=getty-c-w1536","symbol":"IOVA","publisher":"SeekingAlpha","summary":"The FDA decision on IOVA's lifileucel application is delayed until February 2024, but early approval in January is possible. Click here to read my analysis.","url":"https://seekingalpha.com/article/4657500-iovance-biotherapeutics-the-easiest-money-may-have-been-made-but-approval-does-seem-likely"},{"category":"company","date":1702376940,"headline":"A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street","id":124456550,"image":"https://s.yimg.com/ny/api/res/1.2/LuJLc_6C6uCZnT3IP10m3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/130c06b3456ded5c64df19e31d295b7b","symbol":"IOVA","publisher":"Yahoo","summary":"There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock.","url":"https://finance.yahoo.com/news/bull-market-coming-1-stock-102900994.html"},{"category":"company","date":1701966662,"headline":"Why Is Iovance Biotherapeutics (IOVA) Up 53% Since Last Earnings Report?","id":124374312,"image":"https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee","symbol":"IOVA","publisher":"Yahoo","summary":"Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","url":"https://finance.yahoo.com/news/why-iovance-biotherapeutics-iova-53-163102625.html"},{"category":"company","date":1701750784,"headline":"Small Lymphocytic Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, and others.","id":124298265,"image":"","symbol":"IOVA","publisher":"Finnhub","summary":"DelveInsight's, Small Lymphocytic Lymphoma Pipeline Insight 2023 report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It...","url":"https://finnhub.io/api/news?id=950806f5373d12e3a1e57af9deb14a6ce6ac292f3eaec405b9cf831012e1ecee"}]}